Axovant is accelerating the development of innovative gene therapy products that address serious neurological and neuromuscular diseases with significant unmet medical needs. We are currently studying gene therapy candidates for GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases, and Parkinsonâs disease in clinical trials and are working quickly to bring gene therapy candidates for other indications to patients in the clinic. We know that patients canât wait, so neither will we. Source
No articles found.
ALR Technologies is a medical device company providing remote monitoring and care ...
ALR Technologies is a medical device company pr...
Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...
Celsion Corporation is a fully integrated bioph...
TransMedics is a commercial-stage medical technology company transforming organ tr...
TransMedics is a commercial-stage medical techn...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
Athenex is a global oncology focused biopharmaceutical company dedicated to the di...
Athenex is a global oncology focused biopharmac...
Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company ...
Rocket Pharmaceuticals, Inc. is an emerging, cl...
Adverum is a clinical-stage gene therapy company targeting unmet medical need in o...
Adverum is a clinical-stage gene therapy compan...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Assertio Therapeutics is committed to providing responsible solutions to advance p...
Assertio Therapeutics is committed to providing...
Join the National Investor Network and get the latest information with your interests in mind.